Pharmacological profile of (R)-1-[2,3-dihydro-1-(2'-methylphenacyl)-2-oxo- 5-phenyl-1H-1,4-benzodiazepin-3-yl]-3-(3-methylphenyl)urea (YM022), a new potent and selective gastrin/cholecystokinin-B receptor antagonist, in vitro and in vivo.

A Nishida; K Miyata; R Tsutsumi; H Yuki; S Akuzawa; A Kobayashi; T Kamato; H Ito; M Yamano; Y Katuyama

Article Information

vol. 269 no. 2 725-731

PubMed

7910212

Published By

American Society for Pharmacology and Experimental Therapeutics

Print ISSN

0022-3565

Online ISSN

1521-0103

History

Published online May 1, 1994.

Author Information

A Nishida,
K Miyata,
R Tsutsumi,
H Yuki,
S Akuzawa,
A Kobayashi,
T Kamato,
H Ito,
M Yamano and
Y Katuyama

Institute for Drug Discovery Research, Yamanouchi Pharmaceutical Co. Ltd., Ibaraki, Japan.

Statistics from Altmetric.com

Article usage

Article usage: June 2000 to May 2022

	Abstract	Pdf
Jun 2000	4	0
May 2001	4	0
Nov 2001	2	0
Mar 2002	2	0
Apr 2002	1	0
Jun 2002	1	0
Jul 2002	3	0
Sep 2002	2	0
Jan 2003	1	0
Feb 2003	2	0
Jul 2003	7	0
Aug 2003	2	0
Sep 2003	8	0
Oct 2003	3	0
Nov 2003	5	0
Dec 2003	4	0
Jan 2004	15	0
Feb 2004	9	0
Mar 2004	5	0
Apr 2004	8	0
May 2004	9	0
Jun 2004	8	0
Jul 2004	9	0
Aug 2004	15	0
Sep 2004	4	0
Oct 2004	6	0
Nov 2004	10	0
Dec 2004	4	0
Jan 2005	1	0
Feb 2005	7	0
Mar 2005	7	0
Apr 2005	7	0
Jun 2005	2	0
Jul 2005	5	0
Aug 2005	2	0
Sep 2005	3	0
Oct 2005	1	0
Nov 2005	1	0
Dec 2005	3	0
Feb 2006	2	0
Apr 2006	1	1
May 2006	1	0
Jun 2006	2	0
Jul 2006	1	2
Aug 2006	2	0
Sep 2006	3	1
Oct 2006	1	1
Nov 2006	3	2
Dec 2006	1	0
Jan 2007	4	1
Feb 2007	2	1
Mar 2007	4	7
Apr 2007	2	0
May 2007	3	0
Jun 2007	2	0
Jul 2007	1	5
Aug 2007	1	1
Sep 2007	1	4
Oct 2007	4	0
Nov 2007	2	3
Dec 2007	1	0
Jan 2008	1	5
Feb 2008	2	1
Mar 2008	3	1
Apr 2008	3	1
May 2008	0	1
Jun 2008	3	1
Aug 2008	0	3
Sep 2008	1	4
Oct 2008	4	3
Nov 2008	10	1
Dec 2008	2	1
Jan 2009	2	1
Feb 2009	2	1
Mar 2009	2	1
Apr 2009	2	1
May 2009	2	1
Jun 2009	0	2
Jul 2009	2	1
Aug 2009	3	5
Sep 2009	5	1
Oct 2009	8	3
Nov 2009	5	0
Dec 2009	3	0
Jan 2010	1	15
Feb 2010	2	2
Mar 2010	0	7
Apr 2010	1	0
May 2010	2	1
Jun 2010	0	2
Jul 2010	0	2
Aug 2010	3	0
Sep 2010	3	0
Oct 2010	2	0
Nov 2010	2	0
Dec 2010	5	0
Jan 2011	0	2
Feb 2011	3	2
Mar 2011	7	0
Apr 2011	3	0
May 2011	9	1
Jun 2011	3	0
Jul 2011	6	5
Aug 2011	5	0
Sep 2011	1	3
Oct 2011	2	0
Nov 2011	4	0
Dec 2011	2	2
Jan 2012	12	0
Feb 2012	8	2
Mar 2012	9	2
Apr 2012	3	0
May 2012	6	3
Jun 2012	10	1
Jul 2012	5	1
Aug 2012	3	0
Sep 2012	4	0
Oct 2012	4	0
Nov 2012	3	3
Dec 2012	3	1
Jan 2013	5	0
Feb 2013	6	4
Mar 2013	1	0
Apr 2013	4	2
May 2013	4	0
Jun 2013	1	3
Jul 2013	0	1
Aug 2013	0	3
Sep 2013	11	4
Oct 2013	3	3
Nov 2013	3	1
Dec 2013	0	1
Jan 2014	5	5
Feb 2014	6	0
Mar 2014	2	2
Apr 2014	2	3
May 2014	4	1
Jun 2014	2	3
Jul 2014	3	0
Aug 2014	1	2
Sep 2014	1	1
Oct 2014	3	1
Nov 2014	4	3
Dec 2014	4	0
Jan 2015	2	1
Feb 2015	7	3
Mar 2015	6	2
Apr 2015	2	0
Jul 2015	6	6
Aug 2015	2	0
Sep 2015	4	1
Oct 2015	2	2
Nov 2015	0	1
Dec 2015	4	0
Jan 2016	3	1
Feb 2016	79	0
Mar 2016	4	0
May 2016	3	0
Jun 2016	2	0
Jul 2016	5	1
Aug 2016	2	3
Sep 2016	8	2
Oct 2016	61	0
Nov 2016	43	0
Dec 2016	2	0
Jan 2017	15	1
Feb 2017	20	1
Mar 2017	15	0
Apr 2017	32	3
May 2017	38	3
Jun 2017	35	1
Jul 2017	30	1
Aug 2017	11	0
Sep 2017	21	5
Oct 2017	9	0
Nov 2017	6	0
Dec 2017	3	1
Jan 2018	21	1
Feb 2018	8	0
Mar 2018	14	2
Apr 2018	10	1
May 2018	5	0
Jun 2018	2	0
Jul 2018	5	0
Aug 2018	1	0
Sep 2018	4	3
Oct 2018	6	0
Nov 2018	7	0
Jan 2019	1	0
Feb 2019	3	1
Mar 2019	7	2
Apr 2019	2	0
May 2019	3	0
Jun 2019	5	2
Jul 2019	1	0
Aug 2019	3	0
Sep 2019	2	1
Oct 2019	8	1
Nov 2019	5	0
Dec 2019	9	2
Jan 2020	2	0
Feb 2020	3	0
Mar 2020	2	0
May 2020	4	1
Jun 2020	2	0
Jul 2020	2	0
Aug 2020	1	0
Sep 2020	22	0
Oct 2020	2	0
Nov 2020	2	1
Dec 2020	8	0
Jan 2021	7	1
Feb 2021	10	1
Mar 2021	9	0
Apr 2021	9	1
May 2021	14	0
Jun 2021	8	0
Jul 2021	8	0
Aug 2021	50	2
Sep 2021	6	0
Oct 2021	21	0
Nov 2021	17	0
Dec 2021	4	0
Jan 2022	10	0
Feb 2022	6	1
Mar 2022	7	0
Apr 2022	11	0
May 2022	7	1

In this issue

Download PDF

Article Alerts

Email Article

Citation Tools

Main menu

User menu

Search

Pharmacological profile of (R)-1-[2,3-dihydro-1-(2'-methylphenacyl)-2-oxo- 5-phenyl-1H-1,4-benzodiazepin-3-yl]-3-(3-methylphenyl)urea (YM022), a new potent and selective gastrin/cholecystokinin-B receptor antagonist, in vitro and in vivo.

Article Information

Author Information

Statistics from Altmetric.com

Article usage

Article usage: June 2000 to May 2022

In this issue

Pharmacological profile of (R)-1-[2,3-dihydro-1-(2'-methylphenacyl)-2-oxo- 5-phenyl-1H-1,4-benzodiazepin-3-yl]-3-(3-methylphenyl)urea (YM022), a new potent and selective gastrin/cholecystokinin-B receptor antagonist, in vitro and in vivo.

Citation Manager Formats

Pharmacological profile of (R)-1-[2,3-dihydro-1-(2'-methylphenacyl)-2-oxo- 5-phenyl-1H-1,4-benzodiazepin-3-yl]-3-(3-methylphenyl)urea (YM022), a new potent and selective gastrin/cholecystokinin-B receptor antagonist, in vitro and in vivo.

Related Articles

Cited By...

Similar Articles

Navigate

More Information

ASPET's Other Journals

Main menu

User menu

Search

Pharmacological profile of (R)-1-[2,3-dihydro-1-(2'-methylphenacyl)-2-oxo- 5-phenyl-1H-1,4-benzodiazepin-3-yl]-3-(3-methylphenyl)urea (YM022), a new potent and selective gastrin/cholecystokinin-B receptor antagonist, in vitro and in vivo.

Article Information

Author Information

Statistics from Altmetric.com

Article usage

Article usage: June 2000 to May 2022

In this issue

Pharmacological profile of (R)-1-[2,3-dihydro-1-(2'-methylphenacyl)-2-oxo- 5-phenyl-1H-1,4-benzodiazepin-3-yl]-3-(3-methylphenyl)urea (YM022), a new potent and selective gastrin/cholecystokinin-B receptor antagonist, in vitro and in vivo.

Citation Manager Formats

Pharmacological profile of (R)-1-[2,3-dihydro-1-(2'-methylphenacyl)-2-oxo- 5-phenyl-1H-1,4-benzodiazepin-3-yl]-3-(3-methylphenyl)urea (YM022), a new potent and selective gastrin/cholecystokinin-B receptor antagonist, in vitro and in vivo.

Jump to section

Related Articles

Cited By...

Similar Articles

Navigate

More Information

ASPET's Other Journals